Shaymaa Bahnassy

Clinical challenges and proposed solutions for patients with invasive lobular breast cancer Invasive lobular carcinoma (ILC) is the second most common type of breast cancer and is increasingly recognized as a separate entity from invasive breast cancer of no-special type. Here, we present th...

I enjoyed reading this well-thought-out review on clinical challenges and proposed solutions for patients with invasive #lobular #breastcancer Oncologyhttps://www.annalsofoncology.org/article/S0923-7534%2825%2900857-9/fulltext

We did a thing w @jostrander.bsky.social!
Over the last few years, we took a new direction into #lobular breast cancer oncogenesis. We know loss of the gene CDH1 (E-cadherin) is central to ILC, and is among its earliest oncogenic events. But why? How does this push normal breast toward cancer? 1/n

New review from us on radiation in #lobular breast cancer!
www.nature.com/articles/s41...

Lots of anecdote that ILC is highly responsive to XRT (despite ~chemoresistance), but do we have the data?

led by Dr. Michael Boysen (now resident at Trinity Health Ann Arbor), w Dr. Corey Speers @ UAB. 🧵1/n

EMT and cancer: what clinicians should know - Nature Reviews Clinical Oncology Despite several decades of research that has revealed roles in the development and progression of many solid tumours, clinical translation of research targeting epithelial–mesenchymal transition (EMT)...

EMT and cancer: what clinicians should know doi.org/10.1038/s415...

Check out the newest #BreastCancer Research Digest - a summary of last week’s publications from select high-impact journals (May 5th-11th, 2025). #ClinicalResearch #CancerTreatment #BCSM #BreastCancerResearch

Generalized Evolutionary Classifier for Evolutionary Guided Precision Medicine | JCO Precision Oncology PURPOSECurrent precision medicine (CPM) matches patients to therapies using traditional biomarkers, but inevitably resistance develops. Dynamic precision medicine (DPM) is a new evolutionary guided pr...

Can dynamic precision medicine prevent late relapse? A new study published in JCO Precision Oncology delves into the Generalized Evolutionary Classifier and its potential benefits for patients. Read the full article co-authored by @sbahnassy17.bsky.social & @profriggins.bsky.social: brnw.ch/21wRt03

The BRIDGES study @JCO GO

❓ Management of IBC in low and middle income countries
✅ 112 responses from clinicians from 36 counties
🔑 1/3 of patients with non metastatic IBC are receiving TMT
🔑 provider education everywhere is key to improve patient outcomes

ascopubs.org/doi/pdf/10.1...

Diversity in Cancer Research Undergraduate Internship Program - Lombardi Comprehensive Cancer Center Summer 2025 Program About the Program This program, sponsored by the American Cancer Society and Georgetown University, is open to rising college sophomores, juniors and seniors with an interest in ST...

Applications are *now open* for our Summer 2025 American Cancer Society Diversity in Cancer Research *paid* summer internship program at Georgetown Lombardi Comprehensive Cancer! $5K stipend, free campus housing, 10 weeks of hands-on cancer research for undergrads. No citizenship restrictions! 🧪🧬👩‍🔬

AWESOME slide by Dr Michael Danso summing up his approach to HR+ MBC!! #SABCS24

Woman with long dark hair, blue shirt, and dark pants standing in front of a projector screen showing a purple and pink PowerPoint slide with the words “visualizing invasive lobular carcinoma metabolism via fluorescence lifetime imaging.”

Woman with long dark hair, blue shirt, and dark pants standing in front of a projector screen showing her acknowledgment slide, which has a photo of 6 people and the names of researchers who contributed to her study.

Proud of our Riggins Lab undergrad Dua Mobin for an awesome senior research presentation on imaging approaches to visualize #lobular breast cancer metabolism #bcsm @sbahnassy17.bsky.social @sumanranjit.bsky.social @mjsikora.bsky.social @zmadake2.bsky.social